According to GEN news, NGS has a great impact on the expansion of the new generation sequencing market by basis research, and now is changing the revolutionary clinical practice.

Sequencing technology has gone through a long way. Next generation sequencing (NGS) has completely changed the way of human genome sequencing. According to experts, the cost of human genome sequencing in the next few years is expected to be reduced to $1,000. The time and cost of sequencing have been greatly reduced, and the first generation of the human genome project has spent nearly $3 billion. The progress of NGS technology has opened up a new window for clinical diagnosis.

IQ4I Research&Consultancy analyze that the world\’s new generation sequencing market will reach 4.892 billion in 2020. The compound annual growth rate is 20.7%. IQ4I\’s report covers the market revenue and key quantitative analysis of technology, platforms and end users / labs for the NGS market.

Due to the advantages of cost reduction and speed improvement, the application of NGS technology in clinical and individual medical treatment is greatly improved. From the chip to the NGS transformation, the benefits of health care and research methods for the NGS market have brought a great increase. However, the outlook is not entirely bright. The standardization and accuracy of the NGS steps, complexity of data interpretation and storage, the lack of operators and the dependence of NGS on infrastructure are the factors that restrict the development of the technology market.

Instruments and supplies are important parts of the NGS global market, which occupy almost half of the market share in 2013, however, the fastest growing part is the service, with compound annual growth rate is more than 20%.

Global NGS market can be classified as the targeted re-sequencing, whole exome sequencing, RNA sequencing, genome sequencing, chip Seq, de novo genome sequencing and methylation sequencing. Among them, targeted re-sequencing in 2013 occupies the largest share of the targeted market; the fastest growing is the whole exome sequencing, with the annual growth rate of over 25%. Due to the emergence of a large number of disease related NGS tests and platforms, these two technologies have great prospects for development.

According to the IQ4I report, the current academic researchers are the largest NGS users, accounting for about 60% of the market share. However, by 2020, the hospital and clinical applications will be more than 40%. With the growing demand for clinical areas and applications, the market share of NGS in 2020 is expected to increase to 25%.

In the application type, NGS market can be divided into tumor research, genetic screening, infectious disease research, drug and biomarker discovery, molecular epidemiology, agriculture and other aspects of the application. In which the tumor detection in the income and sample capacity accounted for 35% of the market share, the most NGS market share.

North America has the largest share of the global NGS market in 2013. The region will be the fastest growing region in the forecast period, with the highest growth rate in the forecast period.

The principal members of NGS market are thermo, Roche, BGI, CD Genomics, Biomatters software, etc.

Andrea Brook: an author to write blogs for many website, such as CD Genomics, which provides the research community with high quality Next Generation Sequencing, high throughput microarray services. Related link: de novo genome sequencing

Andrea Brook: an author to write blogs for many website, such as CD Genomics, which provides the research community with high quality Next Generation Sequencing, high throughput microarray services. Website: http://www.cd-genomics.com/

Author Bio: Andrea Brook: an author to write blogs for many website, such as CD Genomics, which provides the research community with high quality Next Generation Sequencing, high throughput microarray services. Related link: de novo genome sequencing

Category: Medical Business
Keywords: NGS technology, genome sequencing, IQ4I